A 6‑gene risk score system constructed for predicting the clinical prognosis of pancreatic adenocarcinoma patients

Liu,Yan; Zhu,Dongyan; Xing,Hongjian; Hou,Yi; Sun,Yan

doi:10.3892/or.2019.6979

A 6‑gene risk score system constructed for predicting the clinical prognosis of pancreatic adenocarcinoma patients

Authors:
- Yan Liu
- Dongyan Zhu
- Hongjian Xing
- Yi Hou
- Yan Sun
View Affiliations

Affiliations: Department of Anesthesiology, China Japan Union Hospital, Jilin University, Changchun, Jilin 130033, P.R. China, Department of Vascular Surgery, China Japan Union Hospital, Jilin University, Changchun, Jilin 130033, P.R. China, Department of Orthopedics, China Japan Union Hospital, Jilin University, Changchun, Jilin 130033, P.R. China, Department of Urology, China Japan Union Hospital, Jilin University, Changchun, Jilin 130033, P.R. China
Published online on: January 22, 2019 https://doi.org/10.3892/or.2019.6979
Pages: 1521-1530
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pancreatic adenocarcinoma (PAC) is the most common type of pancreatic cancer, which commonly has an unfavorable prognosis. The present study aimed to develop a novel prognostic prediction strategy for PAC patients. mRNA sequencing data of PAC (the training dataset) were extracted from The Cancer Genome Atlas database, and the validation datasets (GSE62452 and GSE79668) were acquired from the Gene Expression Omnibus database. The differentially expressed genes (DEGs) between good and poor prognosis groups were analyzed by limma package, and then prognosis‑associated genes were screened using Cox regression analysis. Subsequently, the risk score system was constructed and confirmed using Kaplan‑Meier (KM) survival analysis. After the survival associated‑clinical factors were screened using Cox regression analysis, they were performed with stratified analysis. Using DAVID tool, the DEGs correlated with risk scores were conducted with enrichment analysis. The results revealed that there were a total of 242 DEGs between the poor and good prognosis groups. Afterwards, a risk score system was constructed based on 6 prognosis‑associated genes (CXCL11, FSTL4, SEZ6L, SPRR1B, SSTR2 and TINAG), which was confirmed in both the training and validation datasets. Cox regression analysis showed that risk score, targeted molecular therapy, and new tumor (the new tumor event days after the initial treatment according to the TCGA database) were significantly related to clinical prognosis. Under the same clinical condition, 6 clinical factors (age, history of chronic pancreatitis, alcohol consumption, radiation therapy, targeted molecular therapy and new tumor (event days) had significant associations with clinical prognosis. Under the same risk condition, only targeted molecular therapy was significantly correlated with clinical prognosis. In conclusion, the 6‑gene risk score system may be a promising strategy for predicting the outcome of PAC patients.

View Figures

View References

1	Husain K: Pancreatic cancer treatment. Cancer Sci. 5:1100. 2014.
2	Hidalgo M: Pancreatic cancer. N Engl J Med. 362:1605–1617. 2010. View Article : Google Scholar : PubMed/NCBI
3	Maisonneuve P and Lowenfels AB: Risk factors for pancreatic cancer: A summary review of meta-analytical studies. Int J Epidemiol. 44:186–198. 2015. View Article : Google Scholar : PubMed/NCBI
4	Lowenfels AB and Maisonneuve P: Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol. 20:197–209. 2006. View Article : Google Scholar : PubMed/NCBI
5	McGuire S: World cancer report 2014. Geneva, Switzerland: World health organization, international agency for research on cancer, WHO Press, 2015. Adv Nutr. 7:418–419. 2016. View Article : Google Scholar : PubMed/NCBI
6	Bond-Smith G, Banga N, Hammond TM and Imber CJ: Pancreatic adenocarcinoma. BMJ. 344:e24762012. View Article : Google Scholar : PubMed/NCBI
7	Yeo CJ and Cameron JL: Prognostic factors in ductal pancreatic cancer. Langenbecks Arch Surg. 383:129–133. 1998. View Article : Google Scholar : PubMed/NCBI
8	Oshima M, Okano K, Muraki S, Haba R, Maeba T, Suzuki Y and Yachida S: Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer. Ann Surg. 258:336–346. 2013. View Article : Google Scholar : PubMed/NCBI
9	Song W, Tao K, Li H, Jin C, Song Z, Li J, Shi H, Li X, Dang Z and Dou K: Bmi-1 is related to proliferation, survival and poor prognosis in pancreatic cancer. Cancer Sci. 101:1754–1760. 2010. View Article : Google Scholar : PubMed/NCBI
10	Proctor E, Waghray M, Lee CJ, Heidt DG, Yalamanchili M, Li C, Bednar F and Simeone DM: Bmi1 enhances tumorigenicity and cancer stem cell function in pancreatic adenocarcinoma. PLoS One. 8:e558202013. View Article : Google Scholar : PubMed/NCBI
11	Kahlert C, Bergmann F, Beck J, Welsch T, Mogler C, Herpel E, Dutta S, Niemietz T, Koch M and Weitz J: Low expression of aldehyde deyhdrogenase 1A1 (ALDH1A1) is a prognostic marker for poor survival in pancreatic cancer. BMC Cancer. 11:2752011. View Article : Google Scholar : PubMed/NCBI
12	Hoshino Y, Nishida J, Katsuno Y, Koinuma D, Aoki T, Kokudo N, Miyazono K and Ehata S: Smad4 decreases the population of pancreatic cancer-initiating cells through transcriptional repression of ALDH1A1. Am J Pathol. 185:1457–1470. 2015. View Article : Google Scholar : PubMed/NCBI
13	Schaeffer DF, Owen DR, Lim HJ, Buczkowski AK, Chung SW, Scudamore CH, Huntsman DG, Ng SS and Owen DA: Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) overexpression in pancreatic ductal adenocarcinoma correlates with poor survival. BMC Cancer. 10:592010. View Article : Google Scholar : PubMed/NCBI
14	Nguyen Kovochich A, Arensman M, Lay AR, Rao NP, Donahue T, Li X, French SW and Dawson DW: HOXB7 promotes invasion and predicts survival in pancreatic adenocarcinoma. Cancer. 119:529–539. 2013. View Article : Google Scholar : PubMed/NCBI
15	Chile T, Fortes MA, Corrêa-Giannella ML, Brentani HP, Maria DA, Puga RD, de Paula Vde J, Kubrusly MS, Novak EM, Bacchella T, et al: HOXB7 mRNA is overexpressed in pancreatic ductal adenocarcinomas and its knockdown induces cell cycle arrest and apoptosis. BMC Cancer. 13:4512013. View Article : Google Scholar : PubMed/NCBI
16	Zhang Y, Szustakowski J and Schinke M: Bioinformatics analysis of microarray data. Methods Mol Biol. 573:259–284. 2009. View Article : Google Scholar : PubMed/NCBI
17	Kirby MK, Ramaker RC, Gertz J, Davis NS, Johnston BE, Oliver PG, Sexton KC, Greeno EW, Christein JD, Heslin MJ, et al: RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4. Mol Oncol. 10:1169–1182. 2016. View Article : Google Scholar : PubMed/NCBI
18	Yang S, He P, Wang J, Schetter A, Tang W, Funamizu N, Yanaga K, Uwagawa T, Satoskar AR, Gaedcke J, et al: A novel MIF signaling pathway drives the malignant character of pancreatic cancer by targeting NR3C2. Cancer Res. 76:3838–3850. 2016. View Article : Google Scholar : PubMed/NCBI
19	Smyth GK: Limma: Linear models for microarray data. Bioinformatics Comput Biol Solutions Using R and Bioconductor. 397–420. 2005. View Article : Google Scholar
20	Therneau T: A package for survival analysis. R package. 2.37–2. 2012.
21	Kleinbaum DG and Klein M: Kaplan-meier survival curves and the log-rank test. Statistics Biol Health. 45–82. 2012.
22	Gui J and Li H: Penalized Cox regression analysis in the high-dimensional and low-sample size settings, with applications to microarray gene expression data. Bioinformatics. 21:3001–3008. 2005. View Article : Google Scholar : PubMed/NCBI
23	Huang DW, Sherman BT, Tan Q, Collins JR, Alvord WG, Roayaei J, Stephens R, Baseler MW, Lane HC and Lempicki RA: The DAVID gene functional classification tool: A novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol. 8:R1832007. View Article : Google Scholar : PubMed/NCBI
24	Keeley EC, Mehrad B and Strieter RM: CXC chemokines in cancer angiogenesis and metastases. Adv Cancer Res. 106:91–111. 2010. View Article : Google Scholar : PubMed/NCBI
25	Keeley EC, Mehrad B and Strieter RM: Chemokines as mediators of tumor angiogenesis and neovascularization. Exp Cell Res. 317:685–690. 2011. View Article : Google Scholar : PubMed/NCBI
26	Heinrich EL, Lee W, Lu J, Lowy AM and Kim J: Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells. J Transl Med. 10:682012. View Article : Google Scholar : PubMed/NCBI
27	Wente MN, Mayer C, Gaida MM, Michalski CW, Giese T, Bergmann F, Giese NA, Büchler MW and Friess H: CXCL14 expression and potential function in pancreatic cancer. Cancer Lett. 259:209–217. 2008. View Article : Google Scholar : PubMed/NCBI
28	Viloria K, Munasinghe A, Asher S, Bogyere R, Jones L and Hill NJ: A holistic approach to dissecting SPARC family protein complexity reveals FSTL-1 as an inhibitor of pancreatic cancer cell growth. Sci Rep. 6:378392016. View Article : Google Scholar : PubMed/NCBI
29	Trojan L, Schaaf A, Steidler A, Haak M, Thalmann G, Knoll T, Gretz N, Alken P and Michel MS: Identification of metastasis-associated genes in prostate cancer by genetic profiling of human prostate cancer cell lines. Anticancer Res. 25:183–191. 2005.PubMed/NCBI
30	Chalabidchar M, Cassantsourdy S, Duluc C, Fanjul M, Lulka H, Samain R, Roche C, Breibach F, Delisle MB, Poupot M, et al: Loss of somatostatin receptor subtype 2 promotes growth of KRAS-induced pancreatic tumors in mice by activating PI3K signaling and overexpression of CXCL16. Gastroenterology. 148:1452–1465. 2015. View Article : Google Scholar : PubMed/NCBI
31	Du ZY, Qin RY, Xia W, Tian R and Kumar M: Gene transfer of somatostatin receptor type 2 by intratumoral injection inhibits established pancreatic carcinoma xenografts. World J Gastroenterol. 11:516–520. 2005. View Article : Google Scholar : PubMed/NCBI
32	Carrere N, Vernejoul F, Souque A, Asnacios A, Vaysse N, Pradayrol L, Susini C, Buscail L and Cordelier P: Characterization of the bystander effect of somatostatin receptor sst2 after in vivo gene transfer into human pancreatic cancer cells. Human Gene Ther. 16:1175–1193. 2005. View Article : Google Scholar
33	Pigoni M, Wanngren J, Kuhn PH, Munro KM, Gunnersen JM, Takeshima H, Feederle R, Voytyuk I, De Strooper B, Levasseur MD, et al: Seizure protein 6 and its homolog seizure 6-like protein are physiological substrates of BACE1 in neurons. Mol Neurodegener. 11:672016. View Article : Google Scholar : PubMed/NCBI
34	Nishioka M, Kohno T, Takahashi M, Niki T, Yamada T, Sone S and Yokota J: Identification of a 428-kb homozygously deleted region disrupting the SEZ6L gene at 22q12.1 in a lung cancer cell line. Oncogene. 19:6251–6260. 2000. View Article : Google Scholar : PubMed/NCBI
35	Gorlov IP, Meyer P, Liloglou T, Myles J, Boettger MB, Cassidy A, Girard L, Minna JD, Fischer R, Duffy S, et al: Seizure 6-like, SEZ6L) gene and risk for lung cancer. Cancer Res. 67:8406–8411. 2007. View Article : Google Scholar : PubMed/NCBI
36	Tesfaigzi Y, Wright PS and Belinsky SA: SPRR1B overexpression enhances entry of cells into the G₀ phase of the cell cycle. Am J Physiol Lung Cell Mol Physiol. 285:L889–L898. 2003. View Article : Google Scholar : PubMed/NCBI
37	Yoshioka K, Takemura T and Hattori S: Tubulointerstitial nephritis antigen: Primary structure, expression and role in health and disease. Nephron. 90:1–7. 2002. View Article : Google Scholar : PubMed/NCBI
38	Wex T, Lipyansky A, Brömme NC, Wex H, Guan XQ and Brömme D: TIN-ag-RP, a novel catalytically inactive cathepsin B-related protein with EGF domains, is predominantly expressed in vascular smooth muscle cells. Biochemistry. 40:1350–1357. 2001. View Article : Google Scholar : PubMed/NCBI